Acorda Therapeutics (NASDAQ:ACOR) Coverage Initiated by Analysts at StockNews.com

Stock analysts at StockNews.com initiated coverage on shares of Acorda Therapeutics (NASDAQ:ACOR) in a research report issued on Friday. The firm set a “buy” rating on the biopharmaceutical company’s stock.

Acorda Therapeutics Stock Performance

Shares of Acorda Therapeutics stock opened at $0.66 on Friday. Acorda Therapeutics has a one year low of $0.61 and a one year high of $24.20. The firm has a market capitalization of $819,640.00, a price-to-earnings ratio of 0.00 and a beta of 1.40. The business has a 50-day simple moving average of $11.75 and a 200 day simple moving average of $12.36. The company has a debt-to-equity ratio of 3.07, a current ratio of 0.33 and a quick ratio of 0.26.

Institutional Trading of Acorda Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Vanguard Group Inc. bought a new stake in Acorda Therapeutics in the 3rd quarter valued at about $161,000. Deutsche Bank AG bought a new stake in Acorda Therapeutics during the 4th quarter worth approximately $26,000. Prudential Financial Inc. bought a new stake in Acorda Therapeutics during the 2nd quarter worth approximately $28,000. Geode Capital Management LLC increased its holdings in Acorda Therapeutics by 44.8% during the 4th quarter. Geode Capital Management LLC now owns 67,669 shares of the biopharmaceutical company’s stock worth $51,000 after purchasing an additional 20,948 shares in the last quarter. Finally, Virtu Financial LLC bought a new stake in Acorda Therapeutics during the 2nd quarter worth approximately $68,000. 12.71% of the stock is owned by institutional investors.

About Acorda Therapeutics

Acorda Therapeutics, Inc, a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in adults with multiple sclerosis; and Inbrija, an inhaled levodopa for intermittent treatment of OFF periods in people with Parkinson's disease treated with a carbidopa/levodopa regimen.